Sanofi and Translate Bio to Advance MRT5500 into Clinical Study Against COVID-19

 Sanofi and Translate Bio to Advance MRT5500 into Clinical Study Against COVID-19

Sanofi and Translate Bio to Advance MRT5500 into Clinical Study Against COVID-19

Shots:

  • The companies reported the preclinical results of MRT5500 demonstrating the potential of the vaccine in neutralizing the Abs against SARS-CoV-2. The two doses of MRT5500 induced neutralizing antibody levels significantly higher than those observed in COVID-19 patients
  • The preclinical data support the advancement of MRT5500 for clinical development. The companies anticipate the initiation of P-I/II study in Q4’20
  • MRT5500 is being developed under the collaboration between Sanofi Pasteur and Translate Bio and has demonstrated its ability to elicit an immune response in both mice and non-human primates in a preclinical study

Click here ­to­ read full press release/ article | Ref: Sanofi | Image: Business Line

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post